Merck to supply 1.7 million courses of molnupiravir to US
Merck, called MSD outside the US and Canada, has signed an agreement with the US government to supply about 1.7 million courses of molnupiravir (MK-4482) for the treatment
Pharmaceutical company Indivior has collaborated with French biotechnology company Aelis Farma to advance the clinical development of a treatment for cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).